Pyxis Oncology closes public offering with up to $282.6 million in proceeds
Pyxis Oncology completed its registered public offering on October 1, 2026, receiving approximately $110.0 million in upfront gross proceeds before expenses. The company issued 36,047,919 common shares priced at $2.90 each and pre-funded warrants for 1,883,121 shares priced at $2.899 each, along with warrants covering 49,310,352 shares. Cash exercise of all milestone-linked warrants could add approximately $172.6 million, subject to stockholder approval of an authorized-share increase and other conditions.
Why it matters
The financing provides Pyxis Oncology with upfront capital for MICVO development, working capital and general corporate uses. The attached warrants could create additional proceeds and share dilution if their conditions are met and holders exercise them for cash.
Key facts
- 1Pyxis Oncology closed the registered offering on October 1, 2026. globenewswire.com
- 2The transaction generated approximately $110.0 million in upfront gross proceeds before underwriting discounts, commissions and other expenses. globenewswire.com
- 3The company sold 36,047,919 common shares at $2.90 per share and issued pre-funded warrants for 1,883,121 shares at $2.899 per warrant. globenewswire.com
- 4The offering included common warrants covering an aggregate of 49,310,352 shares, with an exercise price of $3.50 per common share. globenewswire.com
- 5Full cash exercise of the milestone-linked warrants would provide approximately $172.6 million in additional gross proceeds, for total gross proceeds of approximately $282.6 million. globenewswire.com
- 6Pyxis Oncology said it plans to use net proceeds for MICVO clinical milestones, including the planned Headliner™ Phase 3 trial, working capital and general corporate purposes. globenewswire.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.